MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) said Wednesday in a press release that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD).
Sunovion believes that further clinical studies would be needed to support a regulatory approval for dasotraline in these indications. It added that dasotraline is considered to be a promising, novel treatment for BED and ADHD.
Sunovion consistently evaluates and prioritizes its pipeline of potential medicines. At this time, the Company has decided not to pursue any further development of dasotraline.
Sunovion remains committed to discovering, developing and commercializing innovative medicines for people living with serious neuropsychiatric conditions.